Lexaria Bioscience Corp. Attending BIO International Convention to Expand Business Development

Kelowna, British Columbia — June 3, 2026 — Leads & Copy — Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in oral drug delivery platforms, announced its participation in the BIO International Convention (BIO) from June 22-25 in San Diego, California. Building on the momentum from the 2025 BIO convention, which catalyzed a significant expansion of its business development program, Lexaria aims to further leverage this year's event to achieve positive outcomes.

Richard Christopher, CEO of Lexaria Bioscience, stated that the company is experiencing unprecedented levels of business development and collaboration interest in its DehydraTECH platform, even prior to the BIO conference. He emphasized the intensive energy and scientific evaluation required for new business relationships to ensure the optimal fit for prospective partners, and that the company is working diligently to generate publicly discussable positive developments.

BIO is recognized as the largest convention of its kind, anticipating over 20,000 attendees from the global pharmaceutical, biotechnology, and supporting sectors, including investors and finance professionals. The convention is a key forum for industry collaborations, with over 66,000 partnering meetings held in 2025. Lexaria has already begun scheduling meetings and anticipates being fully booked due to the strong industry interest in its proprietary DehydraTECH™ drug delivery platform.

Lexaria's attendance at BIO is part of a broader business development initiative launched to inform potential partners about the advantages of DehydraTECH™. While confidential details cannot be disclosed, the program has already initiated collaborative discussions with a diverse range of companies, from emerging biotech developers to established global pharmaceutical corporations.

The company's business development program continues to cultivate additional early-stage leads, with Lexaria committed to thoroughly evaluating each potential relationship. The company will selectively pursue opportunities that align with the best interests of its shareholders and will provide further information as appropriate.

About Lexaria Bioscience Corp. & DehydraTECH:

DehydraTECH™ is Lexaria's patented drug delivery formulation and processing technology designed to enhance the oral absorption of various drugs. Studies have shown DehydraTECH's capability to increase bio-absorption, reduce side-effects, and improve the delivery of certain drugs across the blood-brain barrier. Lexaria operates a licensed in-house research laboratory and possesses a substantial intellectual property portfolio, including 65 granted patents and pending applications worldwide. More information is available at www.lexariabioscience.com.

Source: Lexaria Bioscience Corp.